Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for... Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism.
- Mechanism
- Curator reviewed
Pharmacologically active on 5-hydroxytryptamine receptor 1A, Dopamine receptor D4, and 5-hydroxytryptamine receptor 2B
- Primary indication
- Investigated for the treatment of schizophrenia and schizoaffective disorder.Curator reviewed
- Formula / weight
- C22H25Cl2N3O3 · 450.36 g/mol (avg)
- Code names
- RP-5000 · RP-5063
Resolves to
PMKMNTBZJOXTJW-UHFFFAOYSA-NSMILESClC1=C(Cl)C(=CC=C1)N1CCN(CCCCOC2=CC=C3OCC(=O)NC3=C2)CC1What you can answer from here — as of September 12, 2026
Which drugs share a target with Brilaroxazine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account